Cancer development and progression reflect not only the accumulation of genetic alterations but also pervasive rewiring of gene regulatory programs. Epigenetic mechanisms provide the molecular infrastructure that interprets genetic potential, shaping chromatin accessibility, transcriptional output, cellular plasticity, and phenotypic heterogeneity without altering DNA sequence. Aberrant DNA methylation, distorted histone modification landscapes, dysfunctional chromatin remodeling, and regulatory RNA networks cooperatively establish malignant states that support proliferation, immune evasion, metabolic adaptation, metastasis, and therapy resistance. Importantly, these regulatory alterations can drive profound cell-state transitions even in the absence of additional mutations, underscoring the limits of mutation-centric models of cancer. This review synthesizes current understanding of core epigenetic mechanisms dysregulated in cancer, spanning DNA methylation dynamics, histone modifications, chromatin remodelers, and non-coding RNA-mediated control. It focuses on how these layers intersect with transcription factor networks and three-dimensional genome organization to encode stable yet adaptable regulatory states. Particular emphasis is placed on epigenetic contributions to canonical cancer hallmarks, tumor microenvironment remodeling, and immunometabolic coupling that reinforces immune suppression. Furthermore, the review discusses the latest advances in epigenetic targeted therapy, including DNA methyltransferase and histone deacetylase inhibitors, emerging chromatin reader and remodeler dependencies, and the rationale for combination strategies with chemotherapy, radiotherapy, immunotherapy, or metabolic intervention. Finally, the translational applications of epigenetic biomarkers (especially DNA methylation signatures detectable via liquid biopsy) are explored, which inform early detection, molecular subtyping, prognosis, and therapeutic stratification. Collectively, this review positions epigenetic and gene regulatory landscapes as central determinants of cancer behavior and as actionable leverage points for precision oncology.
1. Zhang J, Zhang S, Wang Y, Zhang X-S. Identification of mutated core cancer modules by integrating somatic mutation, copy number variation, and gene expression data. BMC systems biology. 2013;7(Suppl 2):S4.
2. Tufail M, Jiang C-H, Li N. Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. Signal transduction and targeted therapy. 2025;10(1):227.
3. Ito S, Das ND, Umehara T, Koseki H. Factors and mechanisms that influence chromatin-mediated enhancer–promoter interactions and transcriptional regulation. Cancers. 2022;14(21):5404.
4. Gottlieb B, Babrzadeh F, Oros KK, Alvarado C, Wang C, Gharizadeh B, et al. New insights into the role of intra-tumor genetic heterogeneity in carcinogenesis: identification of complex single gene variance within tumors. Journal of Cancer Metastasis and Treatment. 2018;4:N/A-N/A.
5. Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope FA. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer discovery. 2020;10(12):1808-25.
6. Li S, Peng Y, Panchenko AR. DNA methylation: Precise modulation of chromatin structure and dynamics. Current opinion in structural biology. 2022;75:102430.
7. Millán-Zambrano G, Burton A, Bannister AJ, Schneider R. Histone post-translational modifications—cause and consequence of genome function. Nature Reviews Genetics. 2022;23(9):563-80.
8. Eustermann S, Patel AB, Hopfner K-P, He Y, Korber P. Energy-driven genome regulation by ATP-dependent chromatin remodellers. Nature Reviews Molecular Cell Biology. 2024;25(4):309-32.
9. Srijyothi L, Ponne S, Prathama T, Ashok C, Baluchamy S. Roles of non-coding RNAs in transcriptional regulation. Transcriptional and Post-transcriptional regulation. 2018;55.
10. Akhade VS, Pal D, Kanduri C. Long noncoding RNA: genome organization and mechanism of action. Long Non Coding RNA Biology. 2017:47-74.
11. Morris KV, Mattick JS. The rise of regulatory RNA. Nature Reviews Genetics. 2014;15(6):423-37.
12. Yang J, Zhou F, Luo X, Fang Y, Wang X, Liu X, et al. Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies. Cell Death Discovery. 2025;11(1):84.
13. Andersson R, Sandelin A. Determinants of enhancer and promoter activities of regulatory elements. Nature Reviews Genetics. 2020;21(2):71-87.
14. Rius M, Lyko F. Epigenetic cancer therapy: rationales, targets and drugs. Oncogene. 2012;31(39):4257-65.
15. Zhang A, Miao K, Sun H, Deng C-X. Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance. International journal of biological sciences. 2022;18(7):3019.
16. Lu X, Zhao BS, He C. TET family proteins: oxidation activity, interacting molecules, and functions in diseases. Chemical reviews. 2015;115(6):2225-39.
17. Zhu X, Xiong L, Lyu R, Shen Y, Liu L, Li S, et al. Regulation of TET2 gene expression and 5mC oxidation in breast cancer cells by estrogen signaling. Biochemical and Biophysical Research Communications. 2022;589:240-6.
18. Zhu L, Zhou Q. Aberrant epigenetic regulation of FZD3 by TET2 is involved in ovarian cancer cell resistance to cisplatin. Journal of Chemotherapy. 2024;36(2):143-55.
19. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;99(3):247-57.
20. Wu H, Zhang Y. Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. Genes & development. 2011;25(23):2436-52.
21. Chen F, Zhang Q, Deng X, Zhang X, Chen C, Lv D, et al. Conflicts of CpG density and DNA methylation are proximally and distally involved in gene regulation in human and mouse tissues. Epigenetics. 2018;13(7):721-41.
22. Zhou Y, Yang Z, Zhang H, Li H, Zhang M, Wang H, et al. DNMT3A facilitates colorectal cancer progression via regulating DAB2IP mediated MEK/ERK activation. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2022;1868(4):166353.
23. Adams PD, Jasper H, Rudolph KL. Aging-induced stem cell mutations as drivers for disease and cancer. Cell stem cell. 2015;16(6):601-12.
24. Gao Y, Feng B, Han S, Lu L, Chen Y, Chu X, et al. MicroRNA-129 in human cancers: from tumorigenesis to clinical treatment. Cellular Physiology and Biochemistry. 2016;39(6):2186-202.
25. Weaver IC, Korgan AC, Lee K, Wheeler RV, Hundert AS, Goguen D. Stress and the emerging roles of chromatin remodeling in signal integration and stable transmission of reversible phenotypes. Frontiers in Behavioral Neuroscience. 2017;11:41.
26. Bhat A, Ghatage T, Bhan S, Lahane GP, Dhar A, Kumar R, et al. Role of transposable elements in genome stability: implications for health and disease. International Journal of Molecular Sciences. 2022;23(14):7802.
27. Lobanova O, Rossokha Z, Medvedieva N, Cheshuk V, Vereshchako R, Vershyhora V, et al. Prevalence of BRCA1 and BRCA2 genes promoter hypermethylation in breast cancer tissue. Experimental Oncology. 2021;43(1):56-60.
28. Venugopal K, Feng Y, Shabashvili D, Guryanova OA. Alterations to DNMT3A in hematologic malignancies. Cancer research. 2021;81(2):254-63.
29. Zou R, Lu J, Bai X, Yang Y, Zhang S, Wu S, et al. The epigenetic-modified downregulation of LOXL1 protein mediates EMT in bladder epithelial cells exposed to benzo [a] pyrene and its metabolite BPDE. International Immunopharmacology. 2024;142:113232.
30. Pappalardo XG, Barra V. Losing DNA methylation at repetitive elements and breaking bad. Epigenetics & chromatin. 2021;14(1):25.
31. Sehgal P, Chaturvedi P. Chromatin and cancer: implications of disrupted chromatin organization in tumorigenesis and its diversification. Cancers. 2023;15(2):466.
32. Zou X, Nie S, Cao J, Shi M, Schuck K, Shi Z, et al. ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. Oncogene. 2025;44(40):3774-86.
33. Hai R, He L, Shu G, Yin G. Characterization of histone deacetylase mechanisms in cancer development. Frontiers in oncology. 2021;11:700947.
34. Dai E, Zhu Z, Wahed S, Qu Z, Storkus WJ, Guo ZS. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Molecular cancer. 2021;20(1):171.
35. Park SH, Fong K-W, Mong E, Martin MC, Schiltz GE, Yu J. Going beyond Polycomb: EZH2 functions in prostate cancer. Oncogene. 2021;40(39):5788-98.
36. Zhou W, Xu C, Yang S, Li H, Pan C, Jiang Z, et al. An oncohistone-driven H3. 3K27M/CREB5/ID1 axis maintains the stemness and malignancy of diffuse intrinsic pontine glioma. Nature Communications. 2025;16(1):3675.
37. Tsui Y-M, Chan L-K, Ng IO-L. Cancer stemness in hepatocellular carcinoma: mechanisms and translational potential. British journal of cancer. 2020;122(10):1428-40.
38. Zhu Q, Gu X, Wei W, Wu Z, Gong F, Dong X. BRD9 is an essential regulator of glycolysis that creates an epigenetic vulnerability in colon adenocarcinoma. Cancer Medicine. 2023;12(2):1572-87.
39. Statello L, Guo C-J, Chen L-L, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nature reviews Molecular cell biology. 2021;22(2):96-118.
40. Kumar A, Golani A, Kumar LD. EMT in breast cancer metastasis: an interplay of microRNAs, signaling pathways and circulating tumor cells. Frontiers in Bioscience-Landmark. 2020;25(5):979-1010.
41. Re A, Caselle M, Bussolino F. MicroRNA-mediated regulatory circuits: outlook and perspectives. Physical biology. 2017;14(4):045001.
42. Nalbant E, Akkaya-Ulum YZ. Exploring regulatory mechanisms on miRNAs and their implications in inflammation-related diseases. Clinical and experimental medicine. 2024;24(1):142.
43. Zhu C, Zhang M, Yang W, Gao A, Yu X, Su X, et al. A novel lncRNA, Lnc21q22. 11, suppresses gastric cancer growth by inhibiting MEK/ERK pathway. Epigenetics. 2025;20(1):2512764.
44. Li L, Peng M, Xue W, Fan Z, Wang T, Lian J, et al. Integrated analysis of dysregulated long non-coding RNAs/microRNAs/mRNAs in metastasis of lung adenocarcinoma. Journal of translational medicine. 2018;16(1):372.
45. Lim LJ, Wong SY, Huang F, Lim S, Chong SS, Ooi LL, et al. Roles and regulation of long noncoding RNAs in hepatocellular carcinoma. Cancer Research. 2019;79(20):5131-9.
46. Zhong Y, Du Y, Yang X, Mo Y, Fan C, Xiong F, et al. Circular RNAs function as ceRNAs to regulate and control human cancer progression. Molecular cancer. 2018;17(1):79.
47. Hang D, Zhou J, Qin N, Zhou W, Ma H, Jin G, et al. A novel plasma circular RNA circ FARSA is a potential biomarker for non‐small cell lung cancer. Cancer medicine. 2018;7(6):2783-91.
48. Jiang H, Tian Y, Zhao X, Zhang L, Wu Z. A circular RNA derived from FAT atypical cadherin 3 promotes lung cancer progression via forming a regulatory loop with oncogenic ELAV like RNA binding protein 1. The Journal of Biochemistry. 2022;171(5):519-28.
49. Wang S, Zhang K, Tan S, Xin J, Yuan Q, Xu H, et al. Circular RNAs in body fluids as cancer biomarkers: the new frontier of liquid biopsies. Molecular cancer. 2021;20(1):13.
50. Zhou Y, Wang S, Yin X, Gao G, Wang Q, Zhi Q, et al. TSHZ3 functions as a tumor suppressor by DNA methylation in colorectal cancer. Clinics and Research in Hepatology and Gastroenterology. 2021;45(6):101725.
51. Zhou X, Jin Z, Zhan X, Yang S, Jiang Y, Wang H, et al. Expression of G-quadruplex coordinates BRCA1, CDH1, and RASSF1 via DNA methylation in mouse breast cancer cells. Epigenomics. 2025:1-12.
52. Zhu A, Hopkins KM, Friedman RA, Bernstock JD, Broustas CG, Lieberman HB. DNMT1 and DNMT3B regulate tumorigenicity of human prostate cancer cells by controlling RAD9 expression through targeted methylation. Carcinogenesis. 2021;42(2):220-31.
53. Zhou Y-Q, Jiang J-X, He S, Li Y-Q, Cheng X-X, Liu S-Q, et al. Epstein-Barr virus hijacks histone demethylase machinery to drive epithelial malignancy progression through KDM5B upregulation. Signal Transduction and Targeted Therapy. 2025;10(1):83.
54. Deng X, Qing Y, Horne D, Huang H, Chen J. The roles and implications of RNA m6A modification in cancer. Nature Reviews Clinical Oncology. 2023;20(8):507-26.
55. Zhou Z, Yin X, Sun H, Lu J, Li Y, Fan Y, et al. PTBP1 lactylation promotes glioma stem cell maintenance through PFKFB4-driven glycolysis. Cancer Research. 2025;85(4):739-57.
56. Zhou Z, Gu Y, Yi Z, Wang J, Xiong Z, Guo H, et al. SNORA74A Drives Self‐Renewal of Liver Cancer Stem Cells and Hepatocarcinogenesis Through Activation of Notch3 Signaling. Advanced Science. 2025:2504054.
57. Zhou X, Xia Q, Wang B, Li J, Liu B, Wang S, et al. USP14 modulates stem-like properties, tumorigenicity, and radiotherapy resistance in glioblastoma stem cells through stabilization of MST4-phosphorylated ALKBH5. Theranostics. 2025;15(6):2293.
58. Zhuo B, Zhang Q, Xie T, Wang Y, Chen Z, Zuo D, et al. Integrative epigenetic analysis reveals AP-1 promotes activation of tumor-infiltrating regulatory T cells in HCC. Cellular and Molecular Life Sciences. 2023;80(4):103.
59. Zhu Z-y, Tang N, Wang M-f, Zhou J-c, Wang J-l, Ren H-z, et al. Comprehensive pan-cancer genomic analysis reveals PHF19 as a carcinogenic indicator related to immune infiltration and prognosis of hepatocellular carcinoma. Frontiers in immunology. 2022;12:781087.
60. Zhu K, Zhang FP, Qin C, Song ZX, Yang CN, Lin SS, et al. Targeting the Notch1‐YY1‐ICAM1 Signaling Axis Enhances the Efficacy of Immunotherapy in HCC by Activating CD8+ T‐Cell‐Driven Cancer Cell Pyroptosis. Advanced Science. 2025:e12845.
61. Zhu Y, Zhou Z, Du X, Lin X, Liang Z-M, Chen S, et al. Cancer cell-derived arginine fuels polyamine biosynthesis in tumor-associated macrophages to promote immune evasion. Cancer Cell. 2025;43(6):1045-60. e7.
62. Zhou Z, Li J, Ousmane D, Peng L, Yuan X, Wang J. Metabolic reprogramming directed by super-enhancers in tumors: an emerging landscape. Molecular Therapy. 2024;32(3):572-9.
63. Zou Z, Zheng W, Fan H, Deng G, Lu S-H, Jiang W, et al. Aspirin enhances the therapeutic efficacy of cisplatin in oesophageal squamous cell carcinoma by inhibition of putative cancer stem cells. British Journal of Cancer. 2021;125(6):826-38.
64. Zwamel AH, Ahmad AT, Altalbawy F, Malathi H, Singh A, Jabir MS, et al. Exosomal RNAs and EZH2: unraveling the molecular dialogue driving tumor progression. Medical Oncology. 2025;42(4):1-21.
65. Zhu K, Yao H, Hei J, Li S, Ye T, Jiang W, et al. Tumor exosomal miR-221-3p induces glycolysis through the LIFR/GLUT1 pathway to destroy the cerebral vascular endothelial cell barrier and promote breast cancer brain metastasis. Journal of Translational Medicine. 2025;23(1):1333.
66. Zhou ZW, Zheng W, Xiang Z, Ye CS, Yin QQ, Wang SH, et al. Clinical implications of exosome-derived noncoding RNAs in liver. Laboratory Investigation. 2022;102(5):464-73.
67. Zhu T, Liu J, Beck S, Pan S, Capper D, Lechner M, et al. A pan-tissue DNA methylation atlas enables in silico decomposition of human tissue methylomes at cell-type resolution. Nature methods. 2022;19(3):296-306.
68. Zhu Q, Zhao X, Zhang Y, Li Y, Liu S, Han J, et al. Single cell multi-omics reveal intra-cell-line heterogeneity across human cancer cell lines. Nature Communications. 2023;14(1):8170.
69. Zhu T, Okabe A, Usui G, Fujiki R, Komiyama D, Huang KK, et al. Integrated enhancer regulatory network by enhancer–promoter looping in gastric cancer. NAR cancer. 2024;6(2):zcae020.
70. Zou Z, Iwata M, Yamanishi Y, Oki S. Epigenetic landscape of drug responses revealed through large-scale ChIP-seq data analyses. BMC bioinformatics. 2022;23(1):51.
71. Zou J, Yang W, Li S, Liu F, Chang J, Li W, et al. Combination of LowDose Epigenetic Modifiers and TIC10 for the Activation of Antitumor Immunity and Inhibition of Tumor Growth in Gastrointestinal Cancer. Cancer Medicine. 2025;14(14):e71061.
72. Li T, Chen Y, Li S. The advances in the development of epigenetic modifications therapeutic drugs delivery systems. International Journal of Nanomedicine. 2024:10623-37.
73. Giri AK, Aittokallio T. DNMT inhibitors increase methylation in the cancer genome. Frontiers in pharmacology. 2019;10:385.
74. Mehmood SA, Sahu KK, Sengupta S, Partap S, Karpoormath R, Kumar B, et al. Recent advancement of HDAC inhibitors against breast cancer. Medical Oncology. 2023;40(7):201.
75. Ling R, Wang J, Fang Y, Yu Y, Su Y, Sun W, et al. HDAC-an important target for improving tumor radiotherapy resistance. Frontiers in Oncology. 2023;13:1193637.
76. Menon DR, Hammerlindl H, Torrano J, Schaider H, Fujita M. Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer. Theranostics. 2020;10(14):6261.
77. Garner IM, Brown R. Is there a role for epigenetic therapies in modulating DNA damage repair pathways to enhance chemotherapy and overcome drug resistance? Cancers. 2022;14(6):1533.
78. Wang P, Xiao R, Chen J, Guan P, Heng HL, Liu L, et al. PARP inhibitor augments anti-tumor efficacy of DNMT inhibitor by inducing senescence in cholangiocarcinoma. International Journal of Biological Sciences. 2025;21(8):3649.
79. Wei J, Wang B, Wang H, Meng L, Zhao Q, Li X, et al. Radiation‐induced normal tissue damage: oxidative stress and epigenetic mechanisms. Oxidative medicine and cellular longevity. 2019;2019(1):3010342.
80. Jie C, Li R, Cheng Y, Wang Z, Wu Q, Xie C. Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer. Frontiers in Immunology. 2023;14:1122352.
81. Ivashkiv LB. IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nature Reviews Immunology. 2018;18(9):545-58.
82. An R, Shao Y, Gu W. Mechanistic insights into the role of RNA demethylase ALKBH5 in malignant tumor therapy. Journal of Translational Medicine. 2025;23(1):905.
83. Liang B, Zhang EH, Ye Z, Storts H, Jin W, Zheng X, et al. SIX4 controls anti-PD-1 efficacy by regulating STING expression. Cancer research communications. 2023;3(11):2412-9.
84. Gatti-Mays ME, Gameiro SR, Ozawa Y, Knudson KM, Hicks KC, Palena C, et al. Improving the odds in advanced breast cancer with combination immunotherapy: stepwise addition of vaccine, immune checkpoint inhibitor, chemotherapy, and HDAC inhibitor in advanced stage breast cancer. Frontiers in Oncology. 2021;10:581801.
85. Alam J, Huda MN, Tackett AJ, Miah S. Oncogenic signaling-mediated regulation of chromatin during tumorigenesis. Cancer and Metastasis Reviews. 2023;42(2):409-25.
86. Angus SP, Zawistowski JS, Johnson GL. Epigenetic mechanisms regulating adaptive responses to targeted kinase inhibitors in cancer. Annual review of pharmacology and toxicology. 2018;58(1):209-29.
87. Schvartzman JM, Thompson CB, Finley LW. Metabolic regulation of chromatin modifications and gene expression. Journal of Cell Biology. 2018;217(7):2247-59.
88. Zhou Yl, Liu Xl, Huang SS, Zhang Gm, Jin Xy, Chen L, et al. YAP Upregulation Contributes to Acquired Resistance to BET Inhibitors in Uveal Melanoma. Pigment Cell & Melanoma Research. 2025;38(4):e70036.
89. Sproul D, Meehan RR. Genomic insights into cancer-associated aberrant CpG island hypermethylation. Briefings in functional genomics. 2013;12(3):174-90.
90. Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, et al. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Science translational medicine. 2020;12(524):eaax7533.
91. Gonzalez T, Nie Q, Chaudhary LN, Basel D, Reddi HV. Methylation signatures as biomarkers for non-invasive early detection of breast cancer: A systematic review of the literature. Cancer Genetics. 2024;282:1-8.
92. Gyparaki M-T, Basdra EK, Papavassiliou AG. DNA methylation biomarkers as diagnostic and prognostic tools in colorectal cancer. Journal of molecular medicine. 2013;91(11):1249-56.
93. Wang A, Chen J, Zhou K, He Q, Ji K, Ji X, et al. Identification of LncRNA prognostic biomarkers associated with copy number variants in gastric cancer. 2020.
94. Choi JM, Park C, Chae H. meth-SemiCancer: a cancer subtype classification framework via semi-supervised learning utilizing DNA methylation profiles. BMC bioinformatics. 2023;24(1):168.
95. Suman M, Dugué P-A, Wong EM, Joo JE, Hopper JL, Nguyen-Dumont T, et al. Association of variably methylated tumour DNA regions with overall survival for invasive lobular breast cancer. Clinical epigenetics. 2021;13(1):11.
96. Liu R, Wu J, Guo H, Yao W, Li S, Lu Y, et al. Post‐translational modifications of histones: Mechanisms, biological functions, and therapeutic targets. MedComm. 2023;4(3):e292.
97. Zhou W-m, Liu B, Shavandi A, Li L, Song H, Zhang J-y. Methylation landscape: targeting writer or eraser to discover anti-cancer drug. Frontiers in pharmacology. 2021;12:690057.
98. Țica O, Țica O. Molecular Diagnostics in Heart Failure: From Biomarkers to Personalized Medicine. Diagnostics. 2025;15(14):1807.
